Chief Scientific Officer · FATE THERAPEUTICS INC (FATE)

Daniel Shoemaker

A named executive officer of FATE THERAPEUTICS in every fiscal year CompBrief holds from FY2017 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$2,459,097

Salary $390,000Stock awards $549,750

FY2019: $2,818,586

4th of 5 named executive officers at Fate Therapeutics by FY2020 total.

5 named officers on file for FATE THERAPEUTICS, FY2020

Daniel Shoemaker’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • FATE’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how FATE THERAPEUTICS’s whole pay program stands against its peers

  • FATE THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FATE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 21, 2021 (DEF 14A).

Free

Get Daniel Shoemaker’s full pay file as a PDF — free

More than this page: up to 10 years of Daniel’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Daniel Shoemaker compensation by year

FATE THERAPEUTICS Summary Compensation Table · all 4 fiscal years held
In US dollars, as FATE THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019FY2020
Salary$352,500$365,000$375,000$390,000
Bonus$0$0$0—
Stock awards$0$0$744,750$549,750
Option awards$365,604$842,338$1,547,898$1,324,347
Non-equity incentive$80,194$127,750$150,938$195,000
Pension and deferred compensation$0$0$0$0
All other$0$0$0$0
Total$798,298$1,335,088$2,818,586$2,459,097

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: FATE THERAPEUTICS INC DEF 14A filed April 21, 2021, accession 0001193125-21-124699, and prior-year filings. Open the filing on EDGAR.

How this page was built: the FATE THERAPEUTICS INC filed document, accession 0001193125-21-124699. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2021.

$798K
$1.3M
$2.8M
$2.5M
FY17
FY18
FY19
FY20
SalaryNon-equity incentiveStock awardsOption awards

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU30,000$2,727,900—
RSU25,000$2,273,250—
Option70,313—$16.55
Option69,375—$21.99
Option3,125—$2.73
Option50,375—$6.55

Per the Outstanding Equity Awards at Fiscal Year-End table in FATE THERAPEUTICS INC's FY2020 proxy; value at the fiscal year-end close, as the company printed it.

FATE THERAPEUTICS’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Edward DulacChief Financial Officer(4)$5,683,579
J. Scott WolchkoPresident, Chief Executive Officer and Director$5,600,167
Cindy TahlGeneral Counsel and Corporate Secretary$2,459,097
Daniel Shoemaker · this pageChief Scientific Officer$2,459,097
Bahram ValamehrChief Research and Development Officer$2,459,097

The full FATE THERAPEUTICS compensation record

free company brief

This page is one person within FATE THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the FATE THERAPEUTICS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are FATE THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Daniel Shoemaker's compensation dossier · One-time report. No refunds.